● TTY Biopharm Company Limited

Taiwan and US Pharmaceutical Overview – Policy, Business & TRPMA / Q&A by Lei Chuang, Mark Kao 

Taiwan government plans to invest heavily on the development of Biomedical industry as its top (5 plus 2) priorities.  (The five major industries include the Internet of Things (also known as Asia, Silicon Valley), biomedical, green energy technology, intelligent machinery and the defense industry, plus high value-added agriculture and recycling economy).  However, the biopharmaceutical industry in Taiwan is facing growing pains in capital investment, talent recruitment and strategy to enter the world market. Lei and Mark will speak about the status, challenges and opportunities of Taiwan’s Biopharmaceutical industry.

Development of Anti-HIV Agents by Ming-Tain Lai
A drug discovery program is initiated because there is a disease or clinical condition without suitable medical products available and it is this unmet medical need which is the underlying driving motivation for the project. Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12–15 years and cost in excess of $1-2 billion. This seminar will give an overview of different stages in the new drug discovery including target identification, lead identification, lead optimization, preclinical candidate, and the three phases of clinical trials.  To illustrate these processes, a real world example will be provided on the development of a new anti-HIV agent.

Advancing Chimeric Antigen Receptor T Cell Therapy with CRISPR/Cas9 by Sharon Lin

In August 30th, 2017 FDA has green lighted the first gene therapy, chimeric antigen receptor T cell (CAR-T) therapy targeting CD19 (an antigen expressed on B cells) in acute lymphoblastic lymphoma. FDA approval of CAR-T therapy opens a new era for cancer immunotherapy but there are limitations to overcome. CAR-T is efficacious in treating hematologic malignancies but faces great challenge in treating solid tumor due to tumor microenvironment; the major obstacle in tumor microenvironment is the up-regulation of immune-suppressive receptor. We’ve applied CRISPR knockout to those receptor(s) and observed enhanced anti-tumor activity.   An estimation of half million dollars for each CAR-T infusion reflects a strong urgency for universal CAR-T cells. With CRISPR knocking out endogenous T cell receptor and β2-microglobulin (a component of HLA class I), there had been reduced alloreactivity without graft-versus-host disease observed in mouse Xenograft model. The combination of CAR-T and CRISPR technology is the future direction for cancer immunotherapy and we are currently working on bringing this combination to clinical trial.

How Can Stem Cell Cure Everything And Why My Insurance Does Not Cover It by Chi-Wei Lu
Forever youth and regeneration has been pursued throughout history.  With recent developments in stem cell technology and in vitro organogenesis, new hopes for regeneration is on the rise.  Unavoidably, false claims of stem cell therapy develop concomitantly. An operative definition for stem cell therapy should constitute the direct benefit of tissue regeneration by introducing, reactivating and allowing access of stem cells to the regenerating organ.  Some of the conventional clinical practice fulfills this definition including bone marrow transplantation for leukemia, the Edmund protocol for beta islet cells, and microdrill procedures for joint cartilages. All these technologies enables the regenerative capacity of existing tissue stem cells.      

One of the highlight in the next generation of stem cell therapy is the utilization of pluripotent stem cells, which can now be derived from most cell types of any person, and be induced to form a wide variety of tissue and cell types. Success has been noted in animal models and limited clinical cases, including accelerated recovery from spinal cord injury, age-related macular degeneration and Parkinson’s disease. The next challenge for pluripotent stem cell engineering is formation of functional organ for transplantation.  Organogenesis in culture /or supported by animal chimera complements functional cell-containing, transplantable devices which are in active development for clinical applications.

Medical Device Overview by ​​Allen Y. Wang
Medical Devices is one of the biggest and unprecedented growth industries, driven by innovation and new technologies. It ranges from simple thermometers, to sophisticated imaging systems and degradable surgical implants. This session will provide an overview of Medical Devices, including key players, global trends, and new product development. In addition, three fascinating medical devices specific topics will be presented as follows:


 § Academic Entrepreneurship: Introducing CytoLumina Technologies Corp – A Journey Toward Non-Invasive Cancer Diagnostics,      by Prof. H.R. Tseng, UCLA, USA

 § Taiwan’s public-private partnership-Solid foundation for biomedical start-up, by Dr. Arthur Tsai, ITRI, Taiwan

 § Medical Devices: A Regulatory Viewpoint, by Samantha Mecker, Johnson & Johnson Medical Devices Companies, USA

Swimming with the CRO’s: The Path from Minimum to Better Pharma by Andrew Ho
Much of clinical research tasks previously done by pharmaceutical companies can now be outsourced to CRO's. This has enabled entry of minimally staffed pharmaceutical companies into the realm of early and late phase drug development.  Unfortunately, the reality is that CRO's face the same challenges of talent acquisition, retention, and management that pharmaceutical companies have always faced. The shifting of clinical research to the CRO's additionally created new challenges. This session will begin with a concise survey of current clinical research landscape with the aim of clarifying the root cause of common conflicts between sponsors and CRO's. Specific methods to enable successful collaboration and to accelerate the transition from "Minimum" to "Better" Pharma will be the major focus of the talk.

Considerations of Commercialization of Oral Solid Products and Career Opportunities by Lirong Liu
Diversified disciplines and cumulative experiences augment the commercialization of pharmaceutical products. This complex process creates vast opportunities for various career development in different function areas. This presentation is to share the common grounds based on observations of successful commercialization of pharmaceutical products in the past decades.

Key Considerations in Global Drug Development and Registration- A Regulatory Perspective by Shiao-ling Hung

What does it take to plan a drug development program that will ensure success in global registrations? Hsiao-Ling will share her experience from the two regulatory roles she held- first as an Asia Pacific Latin America Regulatory Leader, then as a North America Regulatory Leader, to give the audience a flavor of long range regulatory strategic planning.

Medical Devices: A Regulatory Viewpoint by Samantha Mecker

Medical device regulatory affairs is a dynamic and constantly evolving space. For professionals experienced in the pharmaceutical sector there are multiple aspects to regulation of these products that are both unique and surprising. In this session we will focus on the top five features of the device regulatory affairs landscape that contributors to global medical product development should know.

Taiwan’s New Initiatives
Thomas Tseng will introduce Taiwan's LEAP program. To learn more about LEAP program, please browsed the program website

Panel Discussion I: Industry Freshman
 The panelists will share their journeys finding their first job in the industry. They will cover the problems and the potential solutions that students may encounter during searching for the first job in the US. You can also expect to learn their job types and how they plan their next steps. 

Panel Discussion II: Advancing in Career

What we will discuss: after starting a career in the industry, what are the nuts and bolts to be successful?

We have five senior-level panelists specialized in different functions, let’s hear their stories on how they demonstrated their skills and abilities to move ahead? 

● Alar Pharmacuticals Inc.

Andrew Ho 何伯容, MD
Head of Psychiatry
SK Life Science

Drug Discovery

Taiwan’s New Initiatives 


21-October-2017 (Saturday)

Time  Activity
  Registration, Sign up for Mock Interview and Breakfast
  Opening Remarks by Mark Kao
  Keynote Speech by Chris Fang 
  Taiwan and US Pharmaceutical Overview – Policy, Business & TRPMA / Q&A
  by Lei Chuang, Mark Kao
  Coffee Break

  Drug Discovery

  Development of Anti-HIV Agents by Ming-Tain Lai



  Advancing Chimeric Antigen Receptor T cell Therapy with CRISPR/Cas9 by Sharon Lin


  Regenerative Medicine 

  How can stem cell cure everything and why my insurance does not cover it by Chi-Wei Lu

  Lunch Break
  Medical Device Overview by Allen Y. Wang

  Medical Device (U.S.)
  Academic Entrepreneurship – A Journey Toward Non-Invasive Cancer Diagnostics by Hsian-Rong        Tseng


  Medical Device (Taiwan)

  Taiwan’s public-private partnership-Solid foundation for biomedical start-up by 

  Yuan Jang (Arthur) Tsai

15:00-15:30  Coffee Break

  Clinical Development

  Swimming with the CRO's: The Path from Minimum to Better Pharma by Andrew Ho



  Considerations of Commercialization of Oral Solid Products and Career Opportunities by Lirong Liu


  Regulatory Affairs


  Key Considerations in Global Drug Development and Registration- A Regulatory Perspective by

  Shiao-ling Hung 


  Medical Devices: A Regulatory Viewpoint by Samantha Mecker​

  Networking Dinner/ Mock Interview

22-October-2017 (Sunday)

Time  Activity
       8:00 – 9:00         Registration and Breakfast
9:00 – 10:00
  Keynote Speech by Eugene Gentile
10:00 – 10:15

​  Taiwan’s New Initiatives by Thomas Tseng

10:15 – 10:30
  Coffee Break
 10:30 – 11:30
  Panel Discussion I – Industry Freshman
  by Chia-Ching (Chad) Chou, ​​Ivan Chen, Nick Chen, Yi-Shan Chen, Yi-Yuan Huang, Yuan-Ping Huang
11:30 – 12:30
  Panel Discussion II – Advancing in Career
  by Allen Y. Wang, Carine C.W. Hsiao, Hsiao-Ling Hung, Nicholas (Hsueh-Fu) Lu, Tsung-Hung Li
 12:30 – 12:45  
  Closing Remarks by Mark Kao 

Past Events

Medical Device (Taiwan) 


Intro of each session

Medical Device (U.S.) 

Yuan-Ping Huang, Ph.D.

Life Science VC Associate,

Lam Capital

Eugene Gentile

Director, Rutgers Business School, Office of Career Management 

​​Ivan Chen, B.Sc.

Analyst, Corporate Strategy & New Ventures, The Advisory Board Company  



Chia-Ching (Chad) Chou, Ph.D.

Research Scientist, Abcam  

Panel Discussion I: Industry Freshman 


In alphabetical order

  • The 2017 TAAB Symposium was held at McDonnell Hall, Princeton University, New Jersey, USA, on October 21-22, 2017. MAP

  • The symposium is expected to attract attendees from highly diverse disciplines including US and Taiwan pharmaceutical biotechnology companies, academic and research institutions.

   (why you must attend? click here)

  • The 2017 TAAB symposium aims to promote information and experience exchange in pharmaceutical and medical device product development in US and Taiwan.

  • The symposium also aims to provide networking and career development opportunities for participants.

​​Allen Y. Wang, Ph.D.
Technical Lead

ETHICON Biosurgery R&D
Johnson & Johnson Medical Devices Companies

Hsiao-Ling Hung, Ph.D. RAC

 North America Regulatory Leader in Oncology
Director, Global Regulatory Affairs
Janssen Pharmaceutical Companies of Johnson & Johnson

Lirong Liu, Ph.D.
Senior Manager

Pfizer Inc.

Keynote Speakers

Minister of Science and Technology

Chi-Wei Lu, Ph.D. CCRP.

Assistant Professor
Dept. of Obstetrics, Gynecology and
Reproductive Services
Director of Research, Women’s Health Institute Rutgers Robert Wood Johnson Medical School


Carine C.W. Hsiao MSc.

Associate Director,

 Franchise Health Economics & Market Access

ETHICON Johnson & Johnson

Panel Discussion II: Advancing in Career 


In alphabetical order

Yi-Shan Chen, Ph.D.


CRISPR Therapeutics

Hsiao-Ling Hung, Ph.D. RAC

 North America Regulatory Leader in Oncology
Director, Global Regulatory Affairs
Janssen Pharmaceutical Companies of Johnson & Johnson

Sharon Lin, Ph.D.
Postdoctoral Fellow

University of Pennsylvania

​​Mark Kao, Ph.D. 

Scientific Director

Janssen R&D

Key Benefits

● Interact with experienced industry colleagues face to face        

● Open communication without language and culture barriers

● Gain first hand info of biopharmaceutical, medical device, AI developments in Taiwan and US 

● Networking with fellow students/postdoc to exchange cutting edge technology information 

New Jersey: Strength Not Only in Biopharmaceutical But Also in Medical Device Industry

"New Jersey is respected globally for its strength in the biopharmaceutical and medical device industry. The State is home to 14 of the world's 20 largest pharmaceutical companies, including Novartis, Johnson & Johnson, Bristol-Myers Squibb, Merck & Co., Novo Nordisk and Bayer Healthcare." - State of New Jersey Business Portal.

Mock Interview

Your work experiences or connection can bring you to an interview, but only a good interview performance can lead you to a job. If you are searching for a job/internship/Co-op, you are encouraged to sign up at the registration table for a 30 min mock interview. You would be asked for your contact information, background and resume and we will arrange an experienced person who best fit to your field to be your interviewer. The interview would be conducted at Princeton University campus after the dinner on the first day of the symposium. 

Coffee Break: Time to Boost Networking Skills​
Networking is a way to learn more about things not on your radar. It could be life experiences, specific knowledges or even job opportunities. We know that networking can be the most nerve-wracking part for some of you, and if that is the case, please don't hesitate to approach any of the 25 symposium organizing committees during each of the coffee break. We will wear noticeable "Q&A" sign for you to easily find us. Come tell us about your story and ask us to "hand-by-hand" prep you to master your networking skills. 

Lunch & Dinner: Eat With The Right People
It's an art to efficiently locate the right people to talk to in a networking environment. The resting/dining areas would be separated into different zones to facilitate people in the same field to find each other. The tentative zones include Marketing and Business Development, Research and Development, Production and Commercialization; Clinical Research and Regulatory Affair. We encourage you to connect and develop a deeper bonding to people in your field. 


Immunotherapy ​(11:45 AM-12:30) 

Nick Chen, Ph.D.

Research Scientist, Elucida Oncology/Memorial Sloan Kettering Cancer Center

Symposium Schedule

Regenerative Medicine 

(11:45 AM-12:30) 

Taiwan and U.S. Pharmaceutical Overview (9:45-10:30) 

2017 TAAB Symposium

Hsian-Rong Tseng, Ph.D.

Crump Institute for Molecular Imaging,

California NanoSystems Institute, University of California-Los Angeles

Thomas Tung-Tse Tseng, Ph.D.

Deputy Director- General
Department of Natural Sciences and Sustainable Development
Ministry of Science & Technology (MOST), TAIWAN ​​

Tsung-Hung Li, Ph.D.

Associate Director

Regulatory Affairs

Merck & Co. Inc.

 Chris Fang 方威凱, MD 

Co-Chairman, Biomedical Development Board of Taiwan

Managing Partner, Amaris Capital

booklet is coming soon !

Nicholas (Hsueh-Fu) Lu MD, MSc
Regional Medical Director

Therapeutic Area Lead for Urology/Women Health Anti-Infective

Pfizer Latin America

Regulatory Affairs: Pharma 


Yi-Yuan Huang, Ph.D.

Technical Account Manager, GenScript USA Inc.

Transportation/Lodging Assist

Regulatory Affairs:

Medical Device 


​​Taiwanese American Association of Biotechnology​

台美生技協會 (TAAB)

Carpool and Lodge Sharing Survey

TAAB would like to provide you a platform to find partners to carpool with and/or to share the hotel room with to reduce your travel cost. Please provide your information in the surveys below and we will connect you with other attendees. TAAB is not subject to the responsibility of the safety issues, please have a thorough discussion with your connected partners before sharing a ride or hotel room with them. Click here for Ride Sharing. Click here for Lodge Sharing and Student Accommodation Aid.

​​Yuan Jang (Arthur) Tsai, Ph.D.
Senior Investigator/Manager
Preclinical Drug Discovery Technology Department
Industrial Technology Research Institute (ITRI, 工研院)

Samantha Mecker, MSc.
Senior Regulatory Affairs Program Lead, ETHICON Biosurgery  Johnson & Johnson

Medical Devices Companies

​​​​Lei Chuang 莊蕾潔, MSc. PMP

Associate Director

Program Management Leader 

Janssen R&D, LLC.


Allen Y. Wang, Ph.D.
Technical Lead

ETHICON Biosurgery R&D
Johnson & Johnson Medical Devices Companies

Ming-Tain Lai, Ph.D.

Senior Principle Scientist

Merck & Co. Inc.

Medical Device Overview 


Why you must attend?

Clinical Development